EP3515456A4 - Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d'anticorps anti-pd-l1 - Google Patents

Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d'anticorps anti-pd-l1 Download PDF

Info

Publication number
EP3515456A4
EP3515456A4 EP17853747.8A EP17853747A EP3515456A4 EP 3515456 A4 EP3515456 A4 EP 3515456A4 EP 17853747 A EP17853747 A EP 17853747A EP 3515456 A4 EP3515456 A4 EP 3515456A4
Authority
EP
European Patent Office
Prior art keywords
responsiveness
compositions
methods
solid tumors
antibody monotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17853747.8A
Other languages
German (de)
English (en)
Other versions
EP3515456A1 (fr
Inventor
Brandon W. Higgs
Chris Morehouse
Philip Brohawn
Katie Streicher
Koustubh Ranade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP3515456A1 publication Critical patent/EP3515456A1/fr
Publication of EP3515456A4 publication Critical patent/EP3515456A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP17853747.8A 2016-09-20 2017-09-19 Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d'anticorps anti-pd-l1 Withdrawn EP3515456A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662397062P 2016-09-20 2016-09-20
PCT/US2017/052246 WO2018057506A1 (fr) 2016-09-20 2017-09-19 Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d'anticorps anti-pd-l1

Publications (2)

Publication Number Publication Date
EP3515456A1 EP3515456A1 (fr) 2019-07-31
EP3515456A4 true EP3515456A4 (fr) 2020-06-17

Family

ID=61691137

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17853747.8A Withdrawn EP3515456A4 (fr) 2016-09-20 2017-09-19 Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d'anticorps anti-pd-l1

Country Status (4)

Country Link
EP (1) EP3515456A4 (fr)
JP (1) JP2019529437A (fr)
CN (1) CN109963572A (fr)
WO (1) WO2018057506A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020610A2 (pt) * 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
WO2021030156A1 (fr) * 2019-08-09 2021-02-18 The Regents Of The University Of California Compositions et procédés de diagnostic et de traitement du cancer de la vessie
WO2023064784A1 (fr) * 2021-10-12 2023-04-20 Foundation Medicine, Inc. Réarrangements de cd274 en tant que prédicteurs de réponse à une thérapie par inhibiteur de point de contrôle immunitaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150071910A1 (en) * 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2016034718A1 (fr) * 2014-09-05 2016-03-10 Medimmune Limited Méthodes d'identification de patients sensibles à un traitement aux anticorps anti-pd-l1 à l'aide de marqueurs (cxcl9, krt8.trim29, et ifngamma.)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3633377A1 (fr) * 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarqueurs et méthodes de traitement d'états associés à pd-1 et pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150071910A1 (en) * 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2016034718A1 (fr) * 2014-09-05 2016-03-10 Medimmune Limited Méthodes d'identification de patients sensibles à un traitement aux anticorps anti-pd-l1 à l'aide de marqueurs (cxcl9, krt8.trim29, et ifngamma.)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B.W.HIGGS ET AL: "High tumoral IFNg mRNA, PD-L1 protein, and combined IFNg mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients", 15LBA, 1 September 2015 (2015-09-01), pages S717, XP055691692, Retrieved from the Internet <URL:https://www.ejcancer.com/article/S0959-8049(16)31937-2/abstract> [retrieved on 20200505] *
See also references of WO2018057506A1 *

Also Published As

Publication number Publication date
EP3515456A1 (fr) 2019-07-31
WO2018057506A1 (fr) 2018-03-29
JP2019529437A (ja) 2019-10-17
CN109963572A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295B1 (en) Antibodies against pd–l1
HK1252955A1 (zh) 針對程序性死亡配體(pd-l1)的單域抗體及其衍生蛋白
EP3325513A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3400243A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3433277A4 (fr) Nouveaux anticorps contre pd-l1
EP3459597A4 (fr) Anticorps à domaine unique anti-ctla4 et protéine dérivée de celui-ci
IL258214A (en) Antibodies - anti-pd-1 and preparations
EP3532100A4 (fr) Anticorps anti-pd-l1 et variants
EP3332006A4 (fr) Nouveaux anticorps anti-pd-l1
EP3242894A4 (fr) Anticorps anti-pd-l1
EP3307777A4 (fr) Nouveaux anticorps anti-pd-l1
EP3515456A4 (fr) Compositions et procédés pour caractériser la réactivité de tumeurs solides à une monothérapie d&#39;anticorps anti-pd-l1
EP3448428A4 (fr) Compositions comprenant une co-formulation d&#39;anticorps anti-pd-l1 et anti-ctla-4
EP3177649A4 (fr) Anticorps anti-pd-l1
EP3060581A4 (fr) Anticorps monoclonaux anti-pd-l1 et fragments de ceux-ci
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3565596A4 (fr) Procédés et compositions se rapportant à des réactifs de type anticorps anti-chi3li
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3310719A4 (fr) Compositions et procédés de préparation d&#39;échantillons analytiques
EP3672636A4 (fr) Procédés et compositions se rapportant à des réactifs d&#39;anticorps anti-chi3l1
EP3373950A4 (fr) Procédés et compositions d&#39;évaluation de spécificités d&#39;anticorps
EP3294341A4 (fr) Compositions et procédés de production de conjugués d&#39;anticorps
EP3464610A4 (fr) Composition de protéine et procédés d&#39;analyse du microbiote
HK1256804A1 (zh) 抗cd154抗體及其使用方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200514

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20200508BHEP

Ipc: A61P 35/00 20060101ALI20200508BHEP

Ipc: C12N 15/113 20100101ALI20200508BHEP

Ipc: A61K 31/7088 20060101AFI20200508BHEP

Ipc: A61K 39/00 20060101ALI20200508BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011692

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201215